The Impact of Stimulatory & Inhibitory Neoantigens Selected with the ATLAS Bioassay: Clinical & Pre-Clinical Results

Time: 9:10 am
day: Day Two


• ATLAS identifies stimulatory and inhibitory CD4+ and CD8+ T cell responses to neoantigens and common antigens

• Preclinical models show the deleterious impact of inhibitory T cell responses on anti-tumor immunity

• Be careful, common neoantigens may differ from common mutations

• The GEN-009 immunotherapy, designed with personalised ATLAS-identified stimulatory neoantigens has resulted in unprecedented breadth of immune response in the ongoing GEN-009-101 Phase 1/2a clinical trial